{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-036283","form_type":"8-K","ticker":"IMCR","cik":"0001671927","company_name":"Immunocore Holdings plc","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.046435+00:00","generated_at":"2026-05-31T11:01:50.908111+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Immunocore reports Q2 2024 revenue growth of 32% driven by KIMMTRAK sales of $75.3 million","bullets":["KIMMTRAK net revenues were $75.3 million in Q2 2024, up 32% year-over-year, driven by US growth and global expansion.","Registrational Phase 3 TEBE-AM trial for KIMMTRAK in cutaneous melanoma converted from Phase 2/3; enrollment completion expected in 1H 2026.","First patient randomized in Phase 3 PRISM-MEL-301 trial evaluating brenetafusp + nivolumab in first-line cutaneous melanoma.","Cash and equivalents at $859.6 million; company plans to repay $50 million loan by end of 2024.","Net loss narrowed to $11.6 million from $17.0 million in prior year quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-036283","json":"https://secwatch.observer/filing/0001140361-24-036283.json","markdown":"https://secwatch.observer/filing/0001140361-24-036283.md","text":"https://secwatch.observer/filing/0001140361-24-036283.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124036283/0001140361-24-036283-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124036283/ef20033789_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:01:50.908111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}